| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0166-3542(02)00018-9 |
| P698 | PubMed publication ID | 12076759 |
| P50 | author | Mike Bray | Q115132999 |
| P2093 | author name string | Robert O Baker | |
| Jo Lynne Raymond | |||
| Tom Geisbert | |||
| P2860 | cites work | Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5'-nor derivatives | Q28343014 |
| Viruses and interferons | Q29620788 | ||
| Inhibition of interferon-mediated antiviral responses by influenza A viruses and other negative-strand RNA viruses | Q33932047 | ||
| Experimental therapy of filovirus infections | Q33957838 | ||
| Differentiation of filoviruses by electron microscopy | Q34063356 | ||
| Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model | Q34068520 | ||
| The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion | Q34234077 | ||
| The Ebola virus VP35 protein functions as a type I IFN antagonist. | Q35422223 | ||
| S-adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents | Q39661538 | ||
| Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus | Q40589954 | ||
| Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice | Q40589958 | ||
| The role of the Type I interferon response in the resistance of mice to filovirus infection | Q40602484 | ||
| Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor | Q40621627 | ||
| 3-deazaadenosine, a S-adenosylhomocysteine hydrolase inhibitor, has dual effects on NF-kappaB regulation. Inhibition of NF-kappaB transcriptional activity and promotion of IkappaBalpha degradation | Q40945823 | ||
| 3-Deazaadenosine analogues inhibit the production of tumour necrosis factor-alpha in RAW264.7 cells stimulated with lipopolysaccharide | Q41146728 | ||
| Influence of S-adenosylhomocysteine hydrolase inhibitors on S-adenosylhomocysteine and S-adenosylmethionine pool levels in L929 cells | Q41714614 | ||
| Carbocyclic adenosine analogues as S-adenosylhomocysteine hydrolase inhibitors and antiviral agents: recent advances | Q42540268 | ||
| Pharmacokinetics of the antiviral agent 3-deazaneplanocin A. | Q42635990 | ||
| A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever | Q43512403 | ||
| Adenosine analogs inhibit the guanine-7-methylation of mRNA cap structures | Q45093368 | ||
| Effects of an S-adenosyl-L-homocysteine hydrolase inhibitor on murine macrophage activation and function | Q72298150 | ||
| P433 | issue | 1 | |
| P921 | main subject | Orthoebolavirus zairense | Q10538943 |
| P304 | page(s) | 151-159 | |
| P577 | publication date | 2002-07-01 | |
| P1433 | published in | Antiviral Research | Q4775352 |
| P1476 | title | 3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice | |
| P478 | volume | 55 |
| Q47573198 | 3,7-Dideazaneplanocin: Synthesis and antiviral analysis |
| Q56786373 | A guided tour through the antiviral drug field |
| Q36295162 | A survey of antiviral drugs for bioweapons |
| Q62383594 | Antiviral Agents Against Ebola Virus Infection: Repositioning Old Drugs and Finding Novel Small Molecules |
| Q33538454 | Antiviral activity of a small-molecule inhibitor of filovirus infection |
| Q38118461 | Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions |
| Q35889586 | Antivirals and antiviral strategies |
| Q56786312 | Antivirals: current state of the art |
| Q40403939 | Binding of the Methyl Donor S-Adenosyl-l-Methionine to Middle East Respiratory Syndrome Coronavirus 2'-O-Methyltransferase nsp16 Promotes Recruitment of the Allosteric Activator nsp10. |
| Q39319904 | Biochemical principles and inhibitors to interfere with viral capping pathways |
| Q38205274 | Characterization of host immune responses in Ebola virus infections |
| Q37945233 | Correlates of immunity to filovirus infection |
| Q38366289 | Curious discoveries in antiviral drug development: the role of serendipity |
| Q33964682 | Defense against filoviruses used as biological weapons |
| Q38546746 | Development of Small-Molecule Antivirals for Ebola |
| Q37828538 | Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses |
| Q33785133 | Discovery, synthesis, and biological evaluation of a novel group of selective inhibitors of filoviral entry |
| Q38707770 | Ebola Virus Disease in Humans: Pathophysiology and Immunity |
| Q34042632 | Ebola virus (EBOV) infection: Therapeutic strategies |
| Q34648461 | Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation |
| Q36315139 | Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. |
| Q24794365 | Ebola virus infection inversely correlates with the overall expression levels of promyelocytic leukaemia (PML) protein in cultured cells |
| Q24597625 | Emerging targets and novel approaches to Ebola virus prophylaxis and treatment |
| Q41943954 | Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice |
| Q33957838 | Experimental therapy of filovirus infections |
| Q37463214 | Fibroblastic reticular cells and their role in viral hemorrhagic fevers |
| Q38599899 | Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus |
| Q26783063 | Filoviruses: One of These Things is (not) Like the Other |
| Q52691809 | Flexibility-Not just for yoga anymore! |
| Q40516689 | Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening |
| Q33804801 | Identification of a small-molecule entry inhibitor for filoviruses |
| Q37584342 | Imino sugar glucosidase inhibitors as broadly active anti-filovirus agents |
| Q38747644 | Implications of Toll-like receptors in Ebola infection |
| Q36509774 | Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus |
| Q41687420 | Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2. |
| Q31055717 | Interferon and its inducers--a never-ending story: "old" and "new" data in a new perspective |
| Q44091038 | John Montgomery's legacy: carbocyclic adenosine analogues as SAH hydrolase inhibitors with broad-spectrum antiviral activity |
| Q43288824 | Looking back in 2009 at the dawning of antiviral therapy now 50 years ago an historical perspective |
| Q37099776 | Molecular strategies to inhibit the replication of RNA viruses |
| Q27011569 | Mouse models for filovirus infections |
| Q92471636 | New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections |
| Q40332893 | Nonhuman primates as models for the discovery and development of ebolavirus therapeutics |
| Q35853406 | Pathogenesis of filoviral haemorrhagic fevers |
| Q38953166 | Pathophysiology of Ebola Virus Infection: Current Challenges and Future Hopes |
| Q34526756 | Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference |
| Q40666918 | Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections |
| Q30230272 | Progress towards the treatment of Ebola haemorrhagic fever |
| Q34040052 | Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. |
| Q40552244 | Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection |
| Q34446169 | Recent highlights in the development of new antiviral drugs |
| Q36714652 | Status and challenges of filovirus vaccines |
| Q91908893 | Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES) |
| Q51667428 | mRNA cap-1 methyltransferase in the SARS genome. |
Search more.